Get the Stockscreener App
82.38
0.55%
0.45
Lemaitre Vascular Inc stock is traded at $82.38, with a volume of 553.27K.
It is up +0.55% in the last 24 hours and down -15.82% over the past month.
LeMaitre Vascular Inc is a provider of medical devices and human tissue cryopreservation services mainly used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and, to a lesser extent, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Its diversified portfolio consists of branded products used in arteries and veins that are well known to vascular surgeons. It operates across the Americas, Europe, the Middle East and Africa, and Asia Pacific, with the majority of its revenue generated from the Americas.
See More
Previous Close:
$81.93
Open:
$81.25
24h Volume:
553.27K
Relative Volume:
1.53
Market Cap:
$1.88B
Revenue:
$256.28M
Net Income/Loss:
$62.40M
P/E Ratio:
30.35
EPS:
2.7139
Net Cash Flow:
$79.12M
1W Performance:
+1.14%
1M Performance:
-15.82%
6M Performance:
-6.02%
1Y Performance:
-14.02%
1-Day Range:
$80.72
$82.61
1-Week Range:
$79.50
$83.07
52-Week Range:
$78.65
$118.01
Lemaitre Vascular Inc Stock (LMAT) Company Profile
Name
Lemaitre Vascular Inc
Sector
Industry
Phone
781-221-2266
Address
63 SECOND AVENUE, BURLINGTON, MA
Compare LMAT vs ISRG, BDX, ALC, RMD, MDLN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LMAT
Lemaitre Vascular Inc
|
82.38 | 1.88B | 256.28M | 62.40M | 79.12M | 2.7139 |
ISRG
Intuitive Surgical Inc
|
394.51 | 141.76B | 11.03B | 3.16B | 3.22B | 8.7251 |
BDX
Becton Dickinson Co
|
183.40 | 50.00B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
74.25 | 35.57B | 10.63B | 819.00M | 1.59B | 1.6577 |
RMD
Resmed Inc
|
224.46 | 32.78B | 5.54B | 1.52B | 1.74B | 10.37 |
MDLN
Medline Inc
|
35.74 | 31.15B | 29.14B | 1.07B | 1.05B | 1.1956 |
Lemaitre Vascular Inc Stock (LMAT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-06-25 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Feb-28-25 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Feb-28-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-13-25 | Initiated | Wells Fargo | Equal Weight |
| Oct-15-24 | Initiated | Cantor Fitzgerald | Neutral |
| Aug-02-24 | Resumed | Lake Street | Buy |
| May-31-24 | Resumed | ROTH MKM | Buy |
| Apr-26-24 | Upgrade | Stifel | Hold → Buy |
| Feb-06-24 | Resumed | KeyBanc Capital Markets | Sector Weight |
| Oct-23-23 | Initiated | JMP Securities | Mkt Outperform |
| Sep-06-23 | Initiated | Oppenheimer | Outperform |
| Aug-03-23 | Downgrade | Jefferies | Buy → Hold |
| May-03-23 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Oct-28-22 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Sep-16-21 | Initiated | Jefferies | Buy |
| Feb-12-21 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Mar-16-20 | Upgrade | Sidoti | Neutral → Buy |
| Oct-24-19 | Downgrade | First Analysis Sec | Strong Buy → Outperform |
| Oct-24-19 | Upgrade | Lake Street | Hold → Buy |
| Oct-14-19 | Upgrade | First Analysis Sec | Outperform → Strong Buy |
| Jul-25-19 | Reiterated | Barrington Research | Outperform |
| Jul-25-19 | Upgrade | First Analysis Sec | Neutral → Outperform |
| Oct-08-18 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Oct-08-18 | Upgrade | ROTH Capital | Neutral → Buy |
| Jun-08-18 | Resumed | ROTH Capital | Buy |
| Apr-26-18 | Downgrade | Stifel | Buy → Hold |
| Apr-26-18 | Upgrade | The Benchmark Company | Hold → Buy |
| Oct-27-17 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| Oct-27-17 | Downgrade | The Benchmark Company | Buy → Hold |
| Jul-10-17 | Downgrade | Canaccord Genuity | Buy → Hold |
| Jul-10-17 | Downgrade | The Benchmark Company | Buy → Hold |
| Mar-21-17 | Initiated | First Analysis Sec | Overweight |
| Feb-22-17 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Sep-22-16 | Downgrade | Sidoti | Buy → Neutral |
| Jul-28-16 | Reiterated | Barrington Research | Outperform |
| Feb-25-16 | Reiterated | Barrington Research | Outperform |
View All
Lemaitre Vascular Inc Stock (LMAT) Latest News
How Investors May Respond To LeMaitre Vascular (LMAT) Trimmed 2026 Outlook Despite Higher Q2 Sales - simplywall.st
Price performance - Yahoo Finance Australia
LeMaitre Vascular remains a Buy despite 31% pul... - Pluang
LeMaitre Vascular: 31% Drawdown On $0.02 Guidance Cut (NASDAQ:LMAT) - Seeking Alpha
The Technical Signals Behind (LMAT) That Institutions Follow - Stock Traders Daily
Quantinno Capital Management LP Buys 18,204 Shares of LeMaitre Vascular, Inc. $LMAT - MarketBeat
LeMaitre Vascular (LMAT) Has A Fresh Update, So Why Is It Drawing Attention? - Sahm
31% Undervalued? LeMaitre Vascular (LMAT) After Earnings Guidance And Dividend Update - Yahoo Finance
LeMaitre Vascular, Inc. Just Missed EarningsBut Analysts Have Updated Their Models - simplywall.st
LeMaitre Vascular (LMAT) Hit by Profit Taking - AlphaStreet
LeMaitre to Participate in the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference - The Manila Times
LeMaitre management to meet investors at virtual Aug. 11 event - Stock Titan
LeMaitre Vascular sales increase 10% to USD 70.4M in Q2 2026 - Medical Buyer
LeMaitre Vascular, Inc. (LMAT) Stock Forecasts - Yahoo Finance
Barrington Upgrades LeMaitre Vascular to Outperform From Market Perform, Price Target is $95 - Yahoo Finance
Stocks making big moves yesterday: LeMaitre, ePlus, Booking, Paymentus, and Vishay Intertechnology - The Globe and Mail
LeMaitre Vascular (LMAT) Stock Price Hit By Revenue Guidance Cut - Sahm
LMAT SWOT Analysis: Strong Financial Growth and Market Position Revealed in 10-Q Filing - GuruFocus
LeMaitre Vascular (NASDAQ:LMAT) Sets New 1-Year Low on Analyst Downgrade - MarketBeat
LeMaitre Vascular stock hits 52-week low at 79.38 USD By Investing.com - Investing.com Nigeria
LeMaitre Vascular stock hits 52-week low at 79.38 USD - Investing.com
LeMaitre Vascular Down Over 22%, On Track for Largest Percent Decrease Since October 2008 -- Data Talk - Moomoo
LMAT Looks 15.2% Undervalued on GF Value™ Despite Recent Sharp P - GuruFocus
LeMaitre Vascular (NASDAQ:LMAT) Price Target Cut to $94.00 by Analysts at Wells Fargo & Company - MarketBeat
Why LeMaitre (LMAT) Shares Are Getting Obliterated Today - TradingView
Why is LeMaitre Vascular stock tumbling today? By Investing.com - Investing.com South Africa
LeMaitre Vascular (NASDAQ:LMAT) Shares Gap Down on Disappointing Earnings - MarketBeat
LeMaitre Vascular, Inc. (NASDAQ:LMAT) Announces $0.25 Quarterly Dividend - MarketBeat
LeMaitre Vascular (NASDAQ:LMAT) Stock Rating Lowered by Barrington Research - MarketBeat
LeMaitre Vascular, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Barrington Downgrades LeMaitre Vascular to Market Perform From Outperform - Yahoo Finance
Royal Bank of Canada Sells 18,448 Shares of LeMaitre Vascular, Inc. $LMAT - MarketBeat
LeMaitre Vascular, Inc. Stock 12‑Month Price Target Cut to $116.25, Implies 10% Upside - TradingView
LeMaitre Vascular Inc (LMAT) (Q2 2026) Earnings Call Highlights: Strong EPS Growth and ... - Yahoo Finance
LEMAITRE VASCULAR, INC. : BARRINGTON RESEARCH CUTS TO MARKET PERFORM FROM OUTPERFORM - Bitget
LeMaitre Vascular Q2 Earnings Call Highlights - MarketBeat
Is LeMaitre Vascular Inc (LMAT) Overvalued After Q2 Earnings Mis - GuruFocus
LeMaitre Vascular (NASDAQ:LMAT) Issues Q3 2026 Earnings Guidance - MarketBeat
LeMaitre Vascular (NASDAQ:LMAT) Posts Earnings Results - marketbeat.com
LeMaitre Vascular (LMAT) Q2 Earnings and Revenues Lag Estimates - finance.yahoo.com
LeMaitre Vascular (NASDAQ:LMAT) Releases Q4 2026 Earnings Guidance - MarketBeat
Earnings call transcript: LeMaitre Vascular slips on Q2 2026 miss, cuts outlook - Investing.com
GUIDANCE: (LMAT) LeMaitre Vascular Expects Full Year 2026 EPS Range $2.84$2.94, Vs. FactSet Est of $3.00 - Moomoo
LeMaitre Vascular Inc reports results for the quarter ended June 30Earnings Summary - TradingView
LeMaitre (NASDAQ:LMAT) Misses Q2 CY2026 Revenue Estimates, Stock Drops 11.6% - Yahoo Finance
Q2 2026 LeMaitre Vascular Inc Earnings Call Transcript - GuruFocus
LeMaitre Vascular (NASDAQ:LMAT) Updates FY 2026 Earnings Guidance - MarketBeat
LeMaitre Q2 2026 sales rise 10 percent to $70.4 million - quiverquant.com
LeMaitre: Q2 Earnings Snapshot - KHOU
LeMaitre Vascular Q2 sales slightly miss estimates - TradingView
LeMaitre Q2 2026 Financial Results - The Manila Times
Lemaitre Vascular Inc Stock (LMAT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.90%
1.18%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):